Prodrugs activated by plasmin and their use in cancer chemotherapy
View Patent ↗The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
1. A pharmaceutical composition comprising:
(1) A compound comprising:
(a) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin and plasmin is present in the extracellular vicinity of the target tumor cell;
(b) an oligopeptide having the formula (AA x ) m -(AA y ) n (SEQ ID NO:1) wherein: (AA x ) m is a plasmin substrate and each AA x independently represents an amino acid; each AA y independently represents an amino acid selected from the group consisting of Ile, Leu, Phe, and Val; m is an integer from 2-4; and n is an integer from 1-2;
(c) a stabilizing group; and
(d) optionally, a linker group not cleavable by plasmin; wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide; wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood; and wherein the compound is cleaved by plasmin under physiological conditions; and
(2) a pharmaceutically acceptable carrier.
2. A compound comprising:
(1) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin and plasmin is present in the extracellular vicinity of the target tumor cell;
(2) an oligopeptide having the formula X-Y, where X is a plasmin peptide substrate of 2-4 amino acids and Y is a peptide comprising 1-2 amino acids each independently selected from the group consisting of Ile, Leu, Phe, and Val;
(3) a stabilizing group; and
(4) optionally, a linker group not cleavable by plasmin; wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide; wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood; and wherein the compound is cleavable by plasmin.
3. The compound of claim 2 wherein plasmin cleaves the linkage between X and Y of the oligopeptide.
4. The compound of claim 2 being a prodrug having an active portion, wherein the active portion of the prodrug is more capable of entering the target cell after cleavage by the plasmin than prior to cleavage by plasmin, the active portion including at least the therapeutic agent.
5. The compound of claim 4 wherein the active portion of the prodrug consists of the therapeutic agent.
6. The compound of claim 4 wherein the active portion of the prodrug includes the therapeutic agent and at least the linker group.
7. The compound of claim 4 wherein the active portion of the prodrug includes the therapeutic agent and one amino acid of the Y portion of the oligopeptide.
8. The compound of claim 7 further comprising two amino acids of the Y portion of the oligopeptide.
9. The compound of claim 2 wherein the oligopeptide is selected from: Leu-Lys-Leu- and Leu-Lys-Leu-Leu (SEQ ID NO:4).
10. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA x4 is an amino acid residue selected from the group consisting of Ile and Phe.
11. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA x3 is an amino acid residue selected from the group consisting of Ala, Glu, Gly, Ile, Leu, Phe, Pro and Val.
12. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA x2 is an amino acid residue selected from the group consisting of Ala, Glu, Gly, Leu, Lys, Phe, Pro and Val.
13. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA x1 is an amino acid residue selected from the group consisting of Arg and Lys.
14. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA y2 and AA y1 are Leu residues.
15. The compound of claim 2 wherein X is (AA x ), and Y is (AA y ) m wherein: each AA x independently represents an amino acid; each AA y independently represents an amino acid; m is an integer from 2-4; n is an integer from 1-2; and AA y1 is a Leu residue and AA y2 is absent.
16. The compound of claim 2 wherein the stabilizing group is selected from the group consisting of D-Ala, P-Ala, .α-methyl-Ala, Succ-D-Ala, Succ-β-Ala and Succ-α-methyl-Ala.
17. The compound of claim 2 wherein the therapeutic agent is daunorubicin.
18. The compound of claim 2 wherein the therapeutic agent is doxorubicin.
19. The compound of claim 2 wherein the therapeutic agent has an intracellular active site.
20. The compound of claim 2 wherein the oligopeptide is directly linked to the therapeutic agent.
21. The compound of claim 2 wherein the oligopeptide is indirectly linked to the therapeutic agent at the second attachment site of the oligopeptide via a linker group, and the linker group is selected from the group consisting of amino caproic acid, hydrazide group, an ester group, an ether group, and a sulphydryl group.
22. A method for treating a patient for a tumor, the method comprising administering to the patient a compound comprising:
(1) a therapeutic agent capable of entering a target tumor cell, wherein said therapeutic agent is daunorubicin or doxorubicin;
(2) an oligopeptide having the formula (AA x ) m (AA y ) n (SEQ ID NO:1) wherein: (AA x ) n is a plasmin substrate and each AA x independently represents an amino acid; each AA y independently represents an amino acid selected from the group consisting of Ile, Leu, Phe, and Val; m is an integer from 2-4; and n is an integer from 1-2;
(3) a stabilizing group; and
(4) optionally, a linker group not cleavable by plasmin; wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide; wherein the stabilizing group hinders cleavage of the oligopeptide by enzymes present in whole blood; wherein plasmin is present in the extracellular vicinity of the target tumor cell and wherein the compound is cleaved by plasmin under physiological conditions.
23. The method of claim 22 wherein the compound is administered intravenously.
24. The method of claim 22 wherein the patient is treated for a medical condition selected from the group consisting of cancer, neoplastic diseases, or tumors.